Delays Plague Breast and Ovarian Cancer Research

Regulations Slow New Drugs Targeting BRCA Mutations

By Karen Iris Tucker

Published August 14, 2012, issue of August 17, 2012.
  • Print
  • Share Share
  • Multi Page

Regulatory hurdles, along with dosing problems, have come to plague a new class of cancer drugs that showed highly encouraging results in early research. Those obstacles have frustrated breast and ovarian cancer patients who are carriers of cancer-causing mutations, particularly prevalent among Ashkenazi Jews, and for whom it was hoped the medicines would prove especially helpful.

Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.
Courtesy Sue Friedman
Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.

Last December, patients eagerly anticipating the completion of trials and FDA approval of Olaparib — then the farthest along in research involving a novel class of therapies called “PARP inhibitors” — were dealt a blow when maker AstraZeneca announced it was, for the time being, discontinuing its late-stage Phase III trial of the drug on patients with serous ovarian cancer, the most common form.

The pharmaceutical company said that Olaparib’s previously reported impressive ability to halt progression of the disease for a time, with limited side effects, would not likely translate into “overall survival benefit,” or the length of time patients live after starting the drug.

No PARP inhibitors are currently in large-scale Phase III trials — the last stage of testing before a company can win FDA approval. But multiple Phase I and II trials are underway. Some early trials indicated that the drugs might prove particularly effective in patients with the inherited BRCA1 or BRCA2 genetic mutations involved in 5% to 10% of all breast and ovarian cancers. With about a one-in-40 chance of carrying a BRCA mutation, Ashkenazi Jews are at higher risk for those diseases compared with those in the general population, where about one in 500 carry a BRCA mutation.

Some academics view the delays in PARP trials as reflective of a contentious change in regulatory policy, regarding how new drugs are evaluated. Dr. Mary Daly, who chairs the department of clinical genetics at Fox Chase Cancer Center in Philadelphia, said: “The move is to thinking that it is not enough to put off progression with a drug, but that the drug has to actually extend life. It’s still somewhat controversial, because some argue that prolonging progression-free survival is valuable in itself.”

Olaparib researchers also reported difficulty in identifying a suitable tablet dose for use in a Phase III trial. AstraZeneca is currently reformulating Olaparib into higher-dose capsules, but the process may significantly delay completion of the clinical trial.

Other PARP inhibitors face similar problems.

“Patients were having to take lots of pills a day to get the appropriate dose,” said Dr. Kristin Zorn, a surgical oncologist at Magee-Womens Hospital of UPMC in Pittsburgh. Zorn is a principal investigator for a study involving Veliparib, a PARP inhibitor being developed by Abbott Laboratories. She said the ideal dose in her Phase II trial is turning out to be much higher than originally thought, but that the study is still enrolling ovarian cancer patients.

The PARP (poly ADP-ribose polymerase) enzyme fixes damage to cells, whether cancerous or not, allowing them to continue to multiply. By interfering with that repair process, PARP inhibitors such as Olaparib and Veliparib make it harder for cancer cells with an abnormal BRCA gene to repair themselves. As a result, the tumor cells accumulate DNA damage, leading to their death.

The potential benefit of PARP inhibitors for patients who carry a BRCA mutation has led to intense interest among this group. In January, breast cancer patients and their advocates were deeply disappointed when Sanofi-Aventis announced that the Phase III trial of its PARP inhibitor, Iniparib, had failed to achieve its “primary survival endpoints”— measurements at a study’s end to see if a given treatment worked. That trial focused on patients with newly diagnosed “triple negative” breast cancer, which does not respond to hormonal treatments.

“Three quarters of BRCA1 breast cancers, especially if [patients] are under the age of 50, are triple negative,” said Daly, adding that, for BRCA2 carriers, the numbers are about 20% to 25%.

Sue Friedman, a 14-year survivor of hereditary breast cancer, is executive director of Facing Our Risk of Cancer Empowered (FORCE), which advocates for those affected by hereditary breast and ovarian cancer. She has watched with frustration the fitful progress of these drugs and contends their stymied path to approval stems, in part, from the failure to design a trial focused solely on BRCA carriers, whom researchers initially had in mind when developing the medicines.

This decision “may have contributed to the fact that the larger studies didn’t meet their primary endpoint,” said Friedman. “My concern is that it may be a while before other companies will develop a new therapy for this community because of the challenges that have been facing PARP inhibitors.”

Zorn, however, contends that large-scale studies with both BRCA carriers and non-carriers will yield the greatest dividends. “We don’t know that the population with BRCA mutations is the only one that benefits from PARPs. We all win if we identify the largest possible group of patients who benefit from a practical standpoint; a pharma company is less likely to pursue FDA approval if only a small select group of patients are candidates.”

She continues to be optimistic about the research, particularly in its value for ovarian cancer, a disease for which there is no effective maintenance medicine since patients invariably become resistant to the treatments. Every year nearly 14,000 women in the U.S. die of the disease.

“Although the path to approval has become much more complicated,” said Zorn, “the value of what we have learned is undiminished.”

Karen Iris Tucker is a freelancer who writes about health, culture and entertainment.Contact her at feedback@forward.com


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • “You can plagiarize the Bible, can’t you?” Jill Sobule says when asked how she went about writing the lyrics for a new 'Yentl' adaptation. “A couple of the songs I completely stole." Share this with the theater-lovers in your life!
  • Will Americans who served in the Israeli army during the Gaza operation face war crimes charges when they get back home?
  • Talk about a fashion faux pas. What was Zara thinking with the concentration camp look?
  • “The Black community was resistant to the Jewish community coming into the neighborhood — at first.” Watch this video about how a group of gardeners is rebuilding trust between African-Americans and Jews in Detroit.
  • "I am a Jewish woman married to a non-Jewish man who was raised Catholic, but now considers himself a “common-law Jew.” We are raising our two young children as Jews. My husband's parents are still semi-practicing Catholics. When we go over to either of their homes, they bow their heads, often hold hands, and say grace before meals. This is an especially awkward time for me, as I'm uncomfortable participating in a non-Jewish religious ritual, but don't want his family to think I'm ungrateful. It's becoming especially vexing to me now that my oldest son is 7. What's the best way to handle this situation?" http://jd.fo/b4ucX What would you do?
  • Maybe he was trying to give her a "schtickle of fluoride"...
  • It's all fun, fun, fun, until her dad takes the T-Bird away for Shabbos.
  • "Like many Jewish people around the world, I observed Shabbat this weekend. I didn’t light candles or recite Hebrew prayers; I didn’t eat challah or matzoh ball soup or brisket. I spent my Shabbat marching for justice for Eric Garner of Staten Island, Michael Brown of Ferguson, and all victims of police brutality."
  • Happy #NationalDogDay! To celebrate, here's a little something from our archives:
  • A Jewish couple was attacked on Monday night in New York City's Upper East Side. According to police, the attackers flew Palestinian flags.
  • "If the only thing viewers knew about the Jews was what they saw on The Simpsons they — and we — would be well served." What's your favorite Simpsons' moment?
  • "One uncle of mine said, 'I came to America after World War II and I hitchhiked.' And Robin said, 'I waited until there was a 747 and a kosher meal.'" Watch Billy Crystal's moving tribute to Robin Williams at last night's #Emmys:
  • "Americans are much more focused on the long term and on the end goal which is ending the violence, and peace. It’s a matter of zooming out rather than debating the day to day.”
  • "I feel great sorrow about the fact that you decided to return the honor and recognition that you so greatly deserve." Rivka Ben-Pazi, who got Dutchman Henk Zanoli recognized as a "Righteous Gentile," has written him an open letter.
  • Is there a right way to criticize Israel?
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.